Clinical Trials on Refractory Waldenstrom Macroglobulinemia

Total 2964 results

National Cancer Institute (NCI)

Completed

Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma

Waldenström Macroglobulinemia | Recurrent Small Lymphocytic Lymphoma | B-cell Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
Centre Hospitalier Universitaire, Amiens
Centre Henri Becquerel; University Hospital, Caen; University Hospital, Lille; Centre...

Withdrawn

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia (SLP-rares)

Waldenstrom Macroglobulinemia | Waldenstrom's Disease

France
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Amgen

Completed

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Multiple Myeloma | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia | Hodgkin's Disease

United States
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
University of Michigan Rogel Cancer Center

Completed

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Myelodysplastic Syndromes | Myeloproliferative Disorders | Lymphoma, Malignant | Waldenstrom's Macroglobulinemia | Myeloma, Plasma-Cell

United States
Cancer Research UK

Completed

A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies

Chronic Lymphocytic Leukaemia | Indolent B-cell Lymphoma | Waldenström Macroglobulinaemia

United Kingdom
French Study Group on Chronic Lymphoid Leukemia
French Innovative Leukemia Organisation; Lymphoma Study Association; Département...

Completed

Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia

Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Lymphoplasmacytic Lymphoma

France
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors

Multiple Myeloma | Non-Hodgkin's Lymphoma (NHL) | Waldenstrom's Macroglobulinemia (WM) | Other B-cell NHL Subtypes, Including WM | T-cell NHL

United States
CHU de Reims

Completed

Transformed Waldenström Macroglobulineamia (tWM)

Transformed Waldenström Macroglobulineamia

France
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States
Dana-Farber Cancer Institute

Active, not recruiting

Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders

Multiple Myeloma | Lymphoblastic Lymphoma | Waldenstrom's Macroglobulinemia | Smoldering Multiple Myeloma

United States
Vertex Pharmaceuticals Incorporated

Completed

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia | Acute Leukemia | Chronic Leukemia

United States
Merck Sharp & Dohme LLC

Recruiting

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Non-Hodgkins Lymphoma | Hematologic Malignancies | Chronic Lymphocytic Leukaemia | Waldenstroms Macroglobulinaemia

Poland, United States, Argentina, Australia, Brazil, Canada, France, Israel, Italy, Spain, Switzerland, Turkey, United Kingdom, Korea, Republic of, Germany, Denmark, China, Romania, Czechia, Hungary, Ireland, Ukraine
Cancer Research UK
BioInvent International AB; Bloodwise

Completed

BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia

B-cell Lymphoma | Waldenström Macroglobulinemia | Chronic Lymphocytic Leukaemia

United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Kosin University Gospel Hospital

Recruiting

R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (Ballondor)

Waldenström's Macroglobulinemia

Korea, Republic of
BeiGene

Completed

A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM) (ASPEN)

Waldenström's Macroglobulinemia

United States, Spain, Australia, France, United Kingdom, Germany, Netherlands, Czechia, Italy, Poland, Belgium, Greece, Sweden
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Multiple Myeloma | Amyloidosis | Waldenstrom's Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States, Spain, France, Canada, Germany, Italy, Australia, United Kingdom, Greece
Yale University

Completed

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)

Multiple Myeloma | Influenza | Waldenstrom's Macroglobulinemia | MGUS | Plasma Cell Disorders

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Waldenstrom... and other conditions

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Recruiting

PROFAST Intervention in Precursor Multiple Myeloma (PROFAST)

Multiple Myeloma | Weight Loss | Fasting | MGUS | Cancer Prevention | Smoldering Waldenstrom Macroglobulinemia(WM)

United States
University of Ulm
Centre Hospitalier de Lens (Co-Sponsor)

Completed

Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

Germany
AEterna Zentaris
Dana-Farber Cancer Institute

Completed

A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström's Macroglobulinemia

Waldenström's Macroglobulinemia

United States
BeiGene

Completed

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)

Waldenström's Macroglobulinemia (WM)

China
David Bond, MD
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
TG Therapeutics, Inc.

Terminated

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Small Lymphocytic Lymphoma | B-cell Lymphomas

United States
Emory University
The Leukemia and Lymphoma Society

Recruiting

Rifaximin in Patients With Monoclonal Gammopathy

Waldenstrom Macroglobulinemia | Light Chain Deposition Disease | IgA Monoclonal Gammopathy | IgG Monoclonal Gammopathy | IgM Monoclonal Gammopathy | Monoclonal Gammopathy | Smoldering Waldenstrom Macroglobulinemia | Gammopathy, Monoclonal | Gammopathy Igg

United States
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
University of Rochester
GlaxoSmithKline

Completed

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

Chronic Lymphocytic Leukemia (CLL) | Waldenstrom Macroglobulinemia (WM)

United States
Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
British Columbia Cancer Agency

Not yet recruiting

Preliminary Assessment of [18F]BL40 in PET/CT Scans

Multiple Myeloma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma

Canada
Gilead Sciences

Completed

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Follicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Indolent Non-Hodgkin Lymphoma | Lymphoplasmacytic Lymphoma (With or Without Waldenstrom Macroglobulinemia)

Japan
BeiGene

Recruiting

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Follicular Lymphoma | Waldenström Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | B-cell Malignancy | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Richter's Transformation | DLBCL Unclassifiable

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
University of Ulm
Pfizer; AbbVie; Ludwig-Maximilians - University of Munich; Zentrum für Klinische... and other collaborators

Not yet recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia (VIWA-1)

Waldenstrom Macroglobulinemia
Dana-Farber Cancer Institute
Eli Lilly and Company

Recruiting

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Sunnybrook Health Sciences Centre
AstraZeneca

Recruiting

Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia (BRAWM)

Waldenstrom Macroglobulinemia

Canada
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Ascentage Pharma Group Inc.

Recruiting

APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia (MAPLE-1)

Waldenstrom Macroglobulinemia

United States, China, Australia
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
Federico II University

Completed

OCT and OCTA Deep Learning in Waldenström's Macroglobulinemia Patients

Waldenstrom Macroglobulinemia

Italy
French Innovative Leukemia Organisation

Completed

Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia (RemodelWM3)

Waldenstrom Macroglobulinemia

France
Hackensack Meridian Health
Onyx Therapeutics, Inc.

Completed

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Waldenstrom Macroglobulinemia

United States

Clinical Trials on Refractory Waldenstrom Macroglobulinemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Argentina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations